1. Altstiel L, Sperber K. Cytokines in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:481–495.

2. Bauer J, Strauss S, Schreiter-Gasser U, et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute phase response in Alzheimer's disease cortices. FEBS Lett 1991;285:111–114.

3. Behl C, Davis J, Cole GM, et al. Vitamin E protects nerve cells from amyloid B protein toxicity. Biochem Biophys Res Commun 1992;186:944–950.

4. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797–811.

5. Caporaso GL, Gancy SE, Buxbaum JD, et al. Chloroquine inhibits intracellular degradation but not secretion of Alzheimer B/A4 amyloid precursor protein. Proc Natl Acad Sci USA 1992;89:2252–2256.

6. Chang TMS, Barre P. Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis. Lancet 1983;1051–1053.

7. Chatellier G, Lacomblez L on behalf of Groupe Francais d'Etude de la Tetrahydroaminoacridine. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer's type: a multi-center trial. Br Med J 1990;495–499.

8. Cheng B, Mattson MP. Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: prevention by NGF and bFGF. Exp Neurol 1992;117:114–123.

9. Clayton RM, Sedowofia SKA, Rankin JM, Manning A. A long term effect of aluminum in the fetal mouse brain. Life Sci 1992;51:1921–1928.

10. Cornfeldt M, Wirtz-Burgger, Szewczak M, Blitzer R, Haroutunian V, Effland RC, Klein JT, Smith C. Abstr Soc Neurosci 1990;16:612.

11. Crutcher KA, Scott SA, Liang S, et al. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J Neurosci 1993;13:2540–2550.

12. Dal-Bianco P, Maly J, Wober C, et al. Galanthamine treatment in Alzheimer's disease. J Neural Transm [Suppl] 1991;59–63.

13. Davidson M, Bierer LM, Kaminsky R, et al. Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study. Alzheimer's Dis Assoc Disord 1989;4:1–4.

14. Davis KL, Hollander E, Davidson M, et al. Induction of depression with oxotremorine in Alzheimer's disease patients. Am J Psychiatry 1987;144:4.

15. Davis KL, Thal LJ, Gamzu E, et al. Tacrine in patients with Alzheimer's disease: a double blind placebo controlled multicenter study. N Engl J Med 1992;327:1374–1379.

16. Eagger S, Morant N, Levy R, Sahakian B. Tacrine in Alzheimer's disease time course of changes in cognitive function and practice effects. Br J Psychiatry 1992;160:36–40.

17. Elrod K, Buccafusco JJ. Correlation of the amnestic effects of nicotinic antagonists with inhibition of regional brain acetylcholine synthesis in rats. J Pharmacol Exp Ther 1991;403–409.

18. Estus S, Golde T, Kunishita T, et al. Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. Science 1992;255:726–730.

19. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;2523–2529.

20. Fielding S, Cornfeldt ML, Szewczak MR, et al. HP-029, a new drug for the treatment of Alzheimer's disease: its pharmacological profile. Presented at fourth world conference on clinical pharmacology and therapeutics, Berlin (West), July 28–30, 1989.

21. Fisher A, Brandeis R, Karton I, et al. (±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3¢)quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. J Pharmacol Exp Ther 1991;392–403.

22. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental-State". A practical method for rating the cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189–198.

23. Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine–lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. N Engl J Med 1990;322:1272–1276.

24. Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain: an immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol 1989;77:569–575.

25. Haratounian V, Kanof PD, Tsuboyama G, et al. Restoration of cholinomimetic activity by clonidine in cholinergic plus adrenergic lesioned rats. Brain Res 1990;507:261–266.

26. Hollander E, Davidson M, Mohs RC, et al. RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects. Biol Psychiatry 1987;22:1067–1078.

27. Hood WF, Sun ET, Compton RP, et al. 1-Aminocyclo-butane 1-carboxylate (ACBC): a specific antagonist of the N-methyl-D-asoartate receptor coupled glycine receptor. Eur J Pharmacol 1989;161:281–282.

28. Jenike MA, Albert MS, Baer L. Oral physostigmine as treatment for Alzheimer's disease: a long term outpatient trial. Alzheimer's Dis Assoc Dis 1990;4(4):226–231.

29. Kruck TPA. Aluminum in Alzheimer's disease. Is there a link? Nature 1993;363(6425):119.

30. Lawlor BA, Davis KL. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? Biol Psychiatry 1992;31:337–350.

31. Leber P. Guidelines for the clinical evaluation of antidementia drugs, first draft. Rockville, MD: US Food and Drug Administration, 1990.

32. Mangoni A, Grassi MP, Frattola L, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer's disease. Eur Neurol 1991;31(2):100–107.

33. Mohs RC. Neuropsychologic assessment of patients with Alzheimer's disease. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology The Fourth Generation of Progress. New York: Raven Press, 1994:1377–1388.

34. Mohs RC, Davis BM, Johns CA, et al. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985; 142:28–33.

35. Monard D. Role of protease inhibition in cellular migration and neuritic growth. Biochem Pharmacol 1987;36:1389–92.

36. McGeer PL, McGeer EG. Complement proteins and complement inhibitors in Alzheimer's disease. Res Immunol 1992;143:621–624.

37. McGeer PL, McGeer EG, Rogers J, et al. Does anti-inflammatory treatment protect against Alzheimer's disease? In: Khachaturian ZS, Blass JP, eds. Alzheimer's disease: new treatment strategies. New York: Marcel Dekker, 1992;165–171.

38. McLachlan Crapper DR, Dalton AJ, Kruck TPA, Bell MY, Smith WL, Kalow W, Andrews DF. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991;337:1304–1308.

39. Murphy MF, Hardiman ST, Nash RJ, et al. Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease. Ann NY Acad Sci 1991;253–262.

40. Newhouse PA, Sunderland T, Tariot PN, et al. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 1988;95:171–175.

41. Nicholson VJ, Tam SW, Myers MJ, et al. DuP996 (3,3-bis(4-pyrindinylmethyl)-1-phenylindolin-2-one) enhances the stimulus-induced release of acetylcholine from rat brain in vitro and in vivo. Drug Rev Res 1990;19:285–300.

42. Nordberg A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res 1992;103–111.

43. Oka A, Belliveau MF, Rosenberg PA, et al. Vulnerability of oligodendroglia to glutamate. Pharmacology, mechanisms, and prevention. J Neurosci 1993;13:1441–153.

44. Olson L, Nordberg A, von Holst H, et al. Nerve growth factor affects C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient. J Neural Transm 1992;4:79–95.

45. Olton DS, Wenk GL. Dementia: animal models of the cognitive impairments produced by degeneration of the basal forebrain cholinergic system. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;941–953.

46. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321:1364–1371.

47. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457–1459.

48. Pomara N, Mendels J, Lewitt PA, et al. Multicenter trial of milacemide in the treatment of Alzheimer's disease. Biol Psychiatry [Suppl] 1991;29:718.

49. Raffaele KC, Berardi A, Morris P, et al. Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal and visuo-spatial function in dementia of the Alzheimer's type. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:643–648.

50. Read SL, Frazee J, Shapira J, et al. Intracerebroventricular bethanechol for Alzheimer's disease. Variable dose-related responses. Arch Neurol 1990;47:1025–1030.

51. Riekkinen P Jr, Sirvio J, Aaltonen M, et al. Effects of concurrent manipulations of nicotinic and muscarinic receptors on spatial and passive avoidance learning. Pharmacol Biochem Behav 1990;405–410.

52. Robakis NK, Anderson JP, Lawrence MR, et al. Expression of the Alzheimer amyloid precursor in brain tissue and effects of NGF and EGF on its metabolism. Clin Neuropharmacol 1991;14 (Suppl):15–23.

53. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609–1611.

54. Rogers J, Schultz J, Brachova L, et al. Complement activation and B-amyloid-mediated neurotoxicity in Alzheimer's disease. Res Immunol 1992;143:624–630.

55. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141(11):1356–1364.

56. Saletu B, Darragh A, Salmon P, et al. EEG brain mapping in evaluating the time course of the central action of DuP 996: a new acetylcholine release drug. Br J Pharmacol 1989;28:1–16.

57. Sapolsky RM, Krey LM, McEwen BS. Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci 1985;5:1222–1227.

58. Sara SJ, Debaugesw B. Idazoxam, an alpha 2 agonist, facilitates memory retrieval in the rat. Behav Neurol Biol 1989;51:401–411.

59. Schneider LS, Olin JT, Pawluczyk S. A double-blind crossover pilot study of L-deprenyl (selegeline) combined with cholinesterase inhibitors in Alzheimer's disease. Am J Psychiatry 1993;150:21–23.

60. Sheardon MJ, Nielsoen EO, Hansen AJ, et al. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 1990;247:571–574.

61. Simpson MDC, Royston MC, Deakin JFW, et al. Regional changes in [H]D-aspartate and [H] TCP binding sites in Alzheimer's disease brains. Brain Res 1988;462:850–852.

62. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to B-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:1977–1981.

63. Sunderland T, Molchan S, Lawlor B, et al. A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl. Int Psychogeriatr 1992;4(Suppl 2):291–309.

64. Suzuki T, Nairn AC, Gandy SE, Greengard P. Neuroscience 1992;48:755–761.

65. Thomsen T, Bickel U, Fischer JP, et al. Galanthamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia 1990;1:46–51.

66. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 1990;27:1133–1142.

67. Vantini G. The pharmacological potential of neurotrophins: a perspective. Psychoneuroendocrinology 1992;17:401–410.

68. Watson GB, Bolanowski MA, Baganoff MP, et al. Glycine antagonist action of 1-aminocyclobutane-1-carboxylate (ACBC) in Xenopus oocytes injected with rat brain mRNA. Eur J Pharmacol 1989;167:291–294.

69. Whitehouse PJ. Neuronal loss and neurotransmitter receptor alterations in Alzheimer's disease. In: Fisher JA, Hanin I, Lachman C, eds. Alzheimer's and Parkinson's diseases: strategies for research and development. New York: Plenum Press, 1986;85–94.

70. Willson RL. Free radical protection: why vitamin E, not vitamin C, B-carotene or glutathione? In: Porter R, Whelan J, eds. Biology of vitamin E. Ciba Foundation Symposium 101. London: Pitman, 1983;19–44.

71. Yasuda RP, Ciesla W, Flores LR, et al. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Mol Pharmacol 43:149–157.